GLENMARK
Active threads
Glenmark Pharma profits surge over 1,000% - CNBC TV18
Pharma major Glenmark Pharmaceuticals Ltd on Friday (July 31) reported a 930% year-on-year increase in consolidated net profit to ₹483 crore for the first quarter, compared with ₹47 crore in the corresponding quarter last year. The company's revenue rose 23% year-on-year to ₹4,018 crore, compared with ₹3,264 crore a year earlier. At the operating level, earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 39% to ₹805 crore from ₹581 crore in the year-ago period.
Glenmark Pharma expands RYALTRIS use to children
2 Min Read Glenmark Pharmaceuticals Ltd. on Tuesday, July 21, said it has received the US Food and Drug Administration (USFDA) approval to expand the use of its RYALTRIS nasal spray for the treatment of seasonal allergic rhinitis in children aged 6 to less than 12 years. The approval extends the use of RYALTRIS, a fixed-dose combination of olopatadine hydrochloride and mometasone furoate, to a younger paediatric population.
Intelligence feed
No articles in the last 24 hours.